MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune diseases, announced it will present a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback